212 related articles for article (PubMed ID: 27890526)
1. Femoropopliteal In-stent Restenosis Repair: Midterm Outcomes After Paclitaxel Eluting Balloon Use (PLAISIR Trial).
Bague N; Julia P; Sauguet A; Pernès JM; Chatelard P; Garbé JF; Penillon S; Cardon JM; Commeau P; Planché O; Guyomarch B; Gouëffic Y
Eur J Vasc Endovasc Surg; 2017 Jan; 53(1):106-113. PubMed ID: 27890526
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
4. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study.
Werner M; Schmidt A; Scheinert S; Banning-Eichenseer U; Ulrich M; Bausback Y; Steiner S; Scheinert D
J Endovasc Ther; 2016 Feb; 23(1):92-7. PubMed ID: 26620399
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.
Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
JACC Cardiovasc Interv; 2012 Mar; 5(3):331-8. PubMed ID: 22440500
[TBL] [Abstract][Full Text] [Related]
7. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
[TBL] [Abstract][Full Text] [Related]
8. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study.
Laird JR; Yeo KK; Rocha-Singh K; Das T; Joye J; Dippel E; Reddy B; Botti C; Jaff MR
Catheter Cardiovasc Interv; 2012 Nov; 80(5):852-9. PubMed ID: 22422738
[TBL] [Abstract][Full Text] [Related]
9. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
Laird JR; Schneider PA; Tepe G; Brodmann M; Zeller T; Metzger C; Krishnan P; Scheinert D; Micari A; Cohen DJ; Wang H; Hasenbank MS; Jaff MR;
J Am Coll Cardiol; 2015 Dec; 66(21):2329-2338. PubMed ID: 26476467
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
11. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
12. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
13. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA "STEnting Long de L'Artère fémorale superficielle" cohort).
Davaine JM; Azéma L; Guyomarch B; Chaillou P; Costargent A; Patra P; Lambert G; Gouëffic Y
Eur J Vasc Endovasc Surg; 2012 Oct; 44(4):432-41. PubMed ID: 22920949
[TBL] [Abstract][Full Text] [Related]
14. Mid-Term Outcomes of Endovascular Treatment for TASC-II D Femoropopliteal Occlusive Disease with Critical Limb Ischemia.
Torres-Blanco Á; Edo-Fleta G; Gómez-Palonés F; Molina-Nácher V; Ortiz-Monzón E
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):344-52. PubMed ID: 26202389
[TBL] [Abstract][Full Text] [Related]
15. A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results.
Micari A; Cioppa A; Vadalà G; Stabile E; Castriota F; Pantaleo P; Grattoni C; Cremonesi A; Marchese A; Rubino P; Biamino G
EuroIntervention; 2011 May; 7 Suppl K():K77-82. PubMed ID: 22027734
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis.
Wu R; Li Z; Wang M; Chang G; Yao C; Wang S
Int J Surg; 2017 Jun; 42():72-82. PubMed ID: 28461145
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.
Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1832-1838. PubMed ID: 28948322
[TBL] [Abstract][Full Text] [Related]
18. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
[TBL] [Abstract][Full Text] [Related]
19. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial.
Bosiers M; Deloose K; Callaert J; Verbist J; Hendriks J; Lauwers P; Schroë H; Lansink W; Scheinert D; Schmidt A; Zeller T; Beschorner U; Noory E; Torsello G; Austermann M; Peeters P
J Endovasc Ther; 2015 Feb; 22(1):1-10. PubMed ID: 25775672
[TBL] [Abstract][Full Text] [Related]
20. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
